Cell Line Cultivation for Cancer Research

LNCaP, 786-0, ACHN and HT1376 cells were obtained from ATCC (Manassas, VA) and were maintained as recommended. C4-2 cells were obtained from Johns Isaacs (Johns Hopkins University, Baltimore, MD) and maintained in RPMI-1640. DPL-S11 cells were maintained in DMEM as previously described [44 (link)]. LMD cells are a derivative of MDA-MB-231 cells and were provided by Sridhar Nimmagadda (Johns Hopkins University, Baltimore, MD). LNCaP-MLuc are stable LNCaP cells derived to express the hMLuc reporter through the hβ-Actin promoter and enhancer; these cells are maintained under blasticidin selection as previously described [45 (link)]. All media contained 10 μg/mL ciprofloxacin hydrochloride (U.S. Biological, Swampscott, MA) and 10% fetal bovine serum.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Wu P., Sokoll L.J., Kudrolli T.A., Chowdhury W.H., Ma R., Liu M.M., Rodriguez R, & Lupold S.E. (2014). A Novel Approach for Detecting Viable and Tissue-specific Circulating Tumor Cells through an Adenovirus-based Reporter Vector. The Prostate, 74(13), 1286-1296.

Publication 2014

LNCaP HT1376 ciprofloxacin hydrochloride

Actin Biological Cells Ciprofloxacin hydrochloride Fetal bovine serum Mda mb 231 cells

Corresponding Organization : Sidney Kimmel Comprehensive Cancer Center

Other organizations : Johns Hopkins Medicine

Top 5 similar protocols

Variable analysis

independent variables

Cell lines used: LNCaP, 786-0, ACHN, HT1376, C4-2, DPL-S11, LMD, LNCaP-MLuc

dependent variables

Not explicitly mentioned

control variables

Media contained 10 μg/mL ciprofloxacin hydrochloride and 10% fetal bovine serum
Cell lines were maintained as recommended or previously described

controls

No positive or negative controls were explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!